A
1.49
0.12 (8.36%)
| Penutupan Terdahulu | 1.38 |
| Buka | 1.39 |
| Jumlah Dagangan | 396,253 |
| Purata Dagangan (3B) | 879,216 |
| Modal Pasaran | 148,988,976 |
| Harga / Jualan (P/S) | 1.67 |
| Harga / Buku (P/B) | 1.60 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2025 - 11 Aug 2025 |
| Margin Keuntungan | -139.74% |
| Margin Operasi (TTM) | -1,216.52% |
| EPS Cair (TTM) | -1.26 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -76.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 43.39% |
| Nisbah Semasa (MRQ) | 3.34 |
| Aliran Tunai Operasi (OCF TTM) | -229.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -92.86 M |
| Pulangan Atas Aset (ROA TTM) | -17.22% |
| Pulangan Atas Ekuiti (ROE TTM) | -90.26% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Alector, Inc. | Menaik | Menurun |
AISkor Stockmoo
1.0
| Konsensus Penganalisis | 3.5 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.00 |
|
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 9.95% |
| % Dimiliki oleh Institusi | 80.82% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Euclidean Capital Llc | 31 Mar 2025 | 1,307,858 |
| Julat 52 Minggu | ||
| Median | 10.00 (571.14%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 May 2025 | 10.00 (571.14%) | Beli | 1.17 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| KENKARE-MITRA SARA | 1.42 | - | 54,725 | 77,710 |
| ROSENTHAL ARNON | 1.42 | - | 137,125 | 194,718 |
| Jumlah Keseluruhan Kuantiti Bersih | 191,850 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 272,427 | |||
| Purata Pembelian Keseluruhan ($) | 1.42 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KENKARE-MITRA SARA | Pegawai | 01 Jul 2025 | Diperolehi (+) | 54,725 | 1.42 | 77,710 |
| ROSENTHAL ARNON | Pegawai | 01 Jul 2025 | Diperolehi (+) | 137,125 | 1.42 | 194,718 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Jun 2025 | Pengumuman | Alector Provides Executive Leadership Update |
| 03 Jun 2025 | Pengumuman | Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference |
| 08 May 2025 | Pengumuman | Alector Reports First Quarter 2025 Financial Results and Provides Business Update |
| 06 May 2025 | Pengumuman | Alector to Participate in Upcoming Healthcare Conferences |
| 17 Apr 2025 | Pengumuman | Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |